HOME >> BIOLOGY >> NEWS
Abgenix reports positive clinical data with ABX-IL8 in Psoriasis

nd autoimmune disorders, cardiovascular disease and cancer. Abgenix has developed XenoMouse technology, which it believes enables quick generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix has collaborative arrangements with multiple pharmaceutical and biotechnology companies involving its XenoMouse technology. In addition, Abgenix has multiple proprietary antibody product candidates that are under development internally, three of which are in human clinical trials.


'"/>

Contact: Kurt Leutzinger, Abgenix
510-608-6575
Porter Novelli
30-Nov-1999


Page: 1 2 3

Related biology news :

1. Abgenix to become sole owner of Xenomouse fully human antibody technology
2. Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs
3. Abgenix initiates phase III clinical trial of graft versus host disease therapy
4. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
5. Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune disease and cancer
6. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
7. APP reports Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere
8. Scientists question reports of massive ant supercolonies in California and Europe
9. Survey reports fall in stem cell transplants for breast cancer
10. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
11. Immerge reports PERVs most infectious to human cells not part of germ-line DNA of mini-swine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/11/2018)... ... October 10, 2018 , ... For the first ... patients to learn about their treatment options. The unique patient education tool seeks ... cancer (TNBC), and was developed through a collaboration between the Centers for ...
(Date:10/5/2018)... ... October 05, 2018 , ... The ... is announcing a 10% price increase across all markets in January 2019. ... the building blocks of protein — for the parenteral nutrition, biopharmaceutical, infant/medical food, ...
(Date:10/5/2018)... LINDA, Calif. (PRWEB) , ... October 04, 2018 , ... ... results of some of the tests such as cardiac troponin has serious clinical complications. ... population, although the exact prevalence is still unknown. , High dose of biotin ...
Breaking Biology News(10 mins):
(Date:10/5/2018)... ... 04, 2018 , ... Power T Handle, LLC, a surgeon-driven, ... Orthopedics This Week during the 2018 National Association of Spine Surgeons (NASS) meeting ... instrument that delivers operating room efficiencies through increased speed and reduced surgeon fatigue ...
(Date:10/2/2018)... BASEL, Switzerland (PRWEB) , ... ... ... leading provider of advanced software solutions for biopharmaceutical R&D, today announced a ... ambr® mini-bioreactor systems from Sartorius, a leading international pharmaceutical and laboratory equipment ...
(Date:9/28/2018)... ... 2018 , ... GlycoMark®, Inc. has announced a partnership with ... the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions ... GlycoMark test to its network of physicians through its sales organization and MD ...
(Date:9/27/2018)... ... September 26, 2018 , ... Nvision Biomedical ... Pedicle Screw System today at the North American Spine Society (NASS) Annual Meeting, ... Nvision focus Pedicle Screw System, which received clearance from the U.S. Food and ...
Breaking Biology Technology:
Cached News: